# Uciane Scarlett

> Uciane Scarlett is a Series A investor at MPM Capital backing Biotechnology and Medical. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [MPM Capital](https://shizune.co/investors/profile/mpm-capital)
- Location: Cambridge, United States
- Total investments: 4
- Last investment: Aug 2021
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/uciane-scarlett-856b2a21/
- X (Twitter): https://twitter.com/UcianeScarlett
- Website: https://x.com/UcianeScarlett

Uciane Scarlett is a Series A investor at MPM Capital in Cambridge focused on Biotechnology and Medical. Uciane Scarlett - Principal @ MPM Capital

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 75% |
| Medical | 2 | 50% |
| Health Care | 1 | 25% |
| Pharmaceutical | 1 | 25% |
| Clinical Trials | 1 | 25% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 50% |
| Seed | 1 | 25% |
| Funding Round | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 2 | 50% |
| United States | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Pepgen | PepGen empowers nucleic acid therapeutics to go the distance. PepGen's ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of their innovative product engine. PepGen's initial focus is on the application of this technology to the efficacious delivery of antisense oligonucleotides,and they are advancing novel conjugate therapeutics to the clinic. | $112.5M |  | Aug 05, 2021 |  |
| T-Cypher Bio | T-Cypher Bio is an early-stage biotechnology company. T-Cypher Bio we believe that TCR-based therapeutics have the potential to transform the treatment of solid tumors, as well as autoimmune, inflammatory, and infectious diseases. Yet challenges in the identification of therapeutically relevant targets and TCRs have limited the application of suchtherapies. T-Cypher’s integrated platform, D-Cypher, overcomes these challenges. |  | Seed | Dec 17, 2020 |  |
| Pepgen | PepGen empowers nucleic acid therapeutics to go the distance. PepGen's ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of their innovative product engine. PepGen's initial focus is on the application of this technology to the efficacious delivery of antisense oligonucleotides,and they are advancing novel conjugate therapeutics to the clinic. | $45M | Series A | Dec 09, 2020 |  |
| Dyne Therapeutics | Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.The company's therapies deliver nucleic acids and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision, enabling patients to restore muscle strength and transform their lives. | $50M | Series A | Apr 03, 2019 |  |

4 of 4 investments shown.

## Co-investors
- [Oxford Science Enterprises](https://shizune.co/investors/profile/oxford-science-enterprises) — VC Fund, 3 deals together
- [CureDuchenne Ventures](https://shizune.co/investors/profile/cureduchenne-ventures) — VC Fund, 2 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 2 deals together
- [Adage Capital Management](https://shizune.co/investors/profile/adage-capital-management) — VC Fund, 1 deal together
- [Deerfield](https://shizune.co/investors/profile/deerfield) — VC Fund, 1 deal together
- [Deerfield Management](https://shizune.co/investors/profile/deerfield-management-83d0) — VC Fund, 1 deal together

## About MPM Capital

VC Fund · Cambridge, United States

MPM Capital is a healthcare investment firm that invests in companies developing therapeutic technologies in oncology. The company invests in life sciences companies that seek to cure diseases by translating science into clinical outcomes. The company prefers to invest in the biotechnology, healthcare, and life sciences sectors.

5 contacts available at MPM Capital.

| Name | Title | Profile |
| --- | --- | --- |
| David P. Ryan | Medical and Scientific Advisor | https://shizune.co/investors/profile/david-p-ryan |
| Detlev Biniszkiewicz | Executive Partner | https://shizune.co/investors/profile/detlev-biniszkiewicz |
| Uciane Scarlett | Principal | https://shizune.co/investors/profile/uciane-scarlett |
| Ansbert Gadicke | Managing Director and Co-Founder | https://shizune.co/investors/profile/ansbert-k-gadicke |
| Bard Geesaman | Managing Director | https://shizune.co/investors/profile/bard-geesaman |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Uciane Scarlett invest in?

Uciane Scarlett invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Seed stage. Most of the 4 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Uciane Scarlett last invest?

The most recent investment recorded for Uciane Scarlett closed in Aug 2021. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co